Tony Hagen

PARP Inhibitors Continue to Show Promise in Ovarian Cancer

November 29, 2017

As PARP inhibitors continue to improve outcomes in patients with ovarian cancer, they may one day be moved into the frontline treatment setting, said Susana M. Campos, M.D., a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School.